Last reviewed · How we verify

Open Label (OL) Paroxetine — Competitive Intelligence Brief

Open Label (OL) Paroxetine (Open Label (OL) Paroxetine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Neurology.

marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Open Label (OL) Paroxetine (Open Label (OL) Paroxetine) — VA Office of Research and Development. Paroxetine selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Open Label (OL) Paroxetine TARGET Open Label (OL) Paroxetine VA Office of Research and Development marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
Lexapro escitalopram Generic (originally Lundbeck/Forest) marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin (5-HT) reuptake transporter 2002-08-14
Prozac fluoxetine Eli Lilly and Company marketed Selective Serotonin Reuptake Inhibitor (SSRI) Serotonin reuptake transporter 1987-12-29
Sertraline HCl Sertraline HCl Tri-Service General Hospital marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
oral escitalopram oral escitalopram NYU Langone Health marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
Selective serotonin re-uptake inhibitor Selective serotonin re-uptake inhibitor New Valley University marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)
sertraline fluvoxamine sertraline fluvoxamine Second Affiliated Hospital, School of Medicine, Zhejiang University marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

  1. University of Texas Southwestern Medical Center · 3 drugs in this class
  2. Johns Hopkins University · 2 drugs in this class
  3. GlaxoSmithKline · 2 drugs in this class
  4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
  5. Guangdong Provincial People's Hospital · 1 drug in this class
  6. Janssen Research & Development, LLC · 1 drug in this class
  7. Medical University of Vienna · 1 drug in this class
  8. Massachusetts General Hospital · 1 drug in this class
  9. Fundació Sant Joan de Déu · 1 drug in this class
  10. Centre Hospitalier Universitaire Dijon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Open Label (OL) Paroxetine — Competitive Intelligence Brief. https://druglandscape.com/ci/open-label-ol-paroxetine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: